Status: Recruiting
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
Participants needed: 126
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: HonorHealth Research InstituteUpdated: Mar 11, 2026Locations: 1
Eligibility criteria
Signed informed consent form (ICF) [+28]
Patients receiving therapy with other anti-neoplastic or experimental agents. [+22]